Search Results - "Noesslinger, T."

SAFETY AND EFFECTIVENESS OF VENETOCLAX MONOTHERAPY IN ELDERLY PATIENTS WITH RELAPSED/REFRACTORY CLL UNDER REAL‐LIFE CONDITIONS – DATA FROM THE OBSERVATIONAL STUDY VERVE by Schwaner, I., Hebart, H., Losem, C., Wolff, T., Huelsenbeck, J., Schmidt, B., Rossi, D., Noesslinger, T.

Get full text

Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q by Mallo, M, Cervera, J, Schanz, J, Such, E, García-Manero, G, Luño, E, Steidl, C, Espinet, B, Vallespí, T, Germing, U, Blum, S, Ohyashiki, K, Grau, J, Pfeilstöcker, M, Hernández, J M, Noesslinger, T, Giagounidis, A, Aul, C, Calasanz, M J, Martín, M L, Valent, P, Collado, R, Haferlach, C, Fonatsch, C, Lübbert, M, Stauder, R, Hildebrandt, B, Krieger, O, Pedro, C, Arenillas, L, Sanz, M Á, Valencia, A, Florensa, L, Sanz, G F, Haase, D, Solé, F

“…This cooperative study assessed prognostic factors for overall survival (OS) and risk of transformation to acute myeloid leukemia (AML) in 541 patients with de…”
Get full text

Monosomal karyotype in MDS: explaining the poor prognosis? by Schanz, J, Tüchler, H, Solé, F, Mallo, M, Luño, E, Cervera, J, Grau, J, Hildebrandt, B, Slovak, M L, Ohyashiki, K, Steidl, C, Fonatsch, C, Pfeilstöcker, M, Nösslinger, T, Valent, P, Giagounidis, A, Aul, C, Lübbert, M, Stauder, R, Krieger, O, Le Beau, M M, Bennett, J M, Greenberg, P, Germing, U, Haase, D

“…Monosomal karyotype (MK) is associated with an adverse prognosis in patients in acute myeloid leukemia (AML). This study analyzes the prognostic impact of MK…”
Get full text

Iron overload in myelodysplastic syndromes (MDS) - diagnosis, management, and response criteria: a proposal of the Austrian MDS platform by Valent, P., Krieger, O., Stauder, R., Wimazal, F., Nösslinger, T., Sperr, W. R., Sill, H., Bettelheim, P., Pfeilstöcker, M.

“…ABSTRACT Transfusion‐related morbidity is an emerging challenge in chronically transfused patients with low‐risk myelodysplastic syndromes (MDS). In these…”
Get full text

Deferasirox induces regression of iron overload in patients with myelodysplastic syndromes by Wimazal, F., Nösslinger, T., Baumgartner, C., Sperr, W. R., Pfeilstöcker, M., Valent, P.

“…Background  Transfusion‐related morbidity is an emerging problem in chronically transfused patients with myelodysplastic syndromes (MDS). Although several…”
Get full text

P019 Time changes in predictive power of established and recently proposed clinical, cytogenetic, and co-morbidity scores in MDS by Tuechler, H, Makrai, A, Noesslinger, T, Pittermann, E, Pfeilstoecker, M

Get full text

154 Some determinants of disease specific mortality in MDS by Noesslinger, T, Tuechler, H, Schoenmetzler, A, Germing, U, Sperr, W.R, Krieger, O, Haase, D, Luebbert, M, Stauder, R, Giagounidis, A, Valent, P, Pfeilstoecker, M

Get full text

P061 Concordant regulation of estrogen receptor, fat metabolism and osteocalcin in myelodysplastic syndromes by Karlic, H, Varga, F, Noesslinger, T, Pittermann, E, Klaushofer, K, Pfeilstoecker, M

Get full text

P020 Refining prognostic systems by comorbidity: are existing scores sufficient for MDS or may specific scores perform better? by Makrai, A, Tuechler, H, Sperr, W, Noesslinger, T, Krieger, O, Stauder, R, Valent, P, Pittermann, E, Pfeilstoecker, M

Get full text

12 Updated cytogenetic risk features in MDS – present state by Haase, D, Schanz, J, Tuechler, H, Sole, F, Mallo, M, Hildebrandt, B, Slovak, M.L, Ohyashiki, K, Steidl, C, Fonatsch, C, Pfeilstoecker, M, Noesslinger, T, Valent, P, Giagounidis, A, Luebbert, M, Stauder, R, Krieger, O, LeBeau, M, Bennett, J, Greenberg, P, Germing, U

Get full text

P018 Host related features explain heterogeneity in risk groups of disease related scoring systems in MDS by Pfeilstoecker, M, Tuechler, H, Makrai, A, Germing, U, Sperr, W, Krieger, O, Haase, D, Luebbert, M, Stauder, R, Giagounidis, A, Valent, P, Noesslinger, T

Get full text

P007 Attempts to define a No Risk subgroup in MDS by examining relative survival in well known scoring systems by Noesslinger, T, Tuechler, H, Makrai, A, Germing, U, Sperr, W, Krieger, O, Haase, D, Luebbert, M, Stauder, R, Giagounidis, A, Valent, P, Pfeilstoecker, M

Get full text

C005 Prognostic impact of the proportion of aberrant metaphases in patients with a primary myelodysplastic syndrome by Mallo, M, Cervera, J, Schanz, J, Espinet, B, Duch, E, Luño, E, Steidl, C, Martín, M.L, Germing, U, Grau, J, Pfeilstoecker, M, Hernández-Rivas, J.M, Noesslinger, T, Calasanz, M.J, Collado, R, Fonatsch, C, Bureo, E, Lübbert, M, Ríos, R, Stauder, R, Arranz, E, Hildebrandt, B, Slovak, M, Cigudosa, J.C, Krieger, O, Pedro, C, Salido, M, Arenillas, L, Sanz, G.F, Sanz, M.Á, Valencia, A, Florensa, L, Novell, L, del Cañizo, C, García-Manero, G, Vallespí, T, Ohyashiki, K, Benlloch, L, Haase, D, Solé, F

Get full text

Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group by Sperr, W. R., Wimazal, F., Kundi, M., Baumgartner, C., Nösslinger, T., Makrai, A., Stauder, R., Krieger, O., Pfeilstöcker, M., Valent, P.

“…Background: The evaluation of comorbidity is of increasing importance in patients with hematologic disorders. Patients and methods: In the present study, the…”
Get full text

Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study by Germing, U, Lauseker, M, Hildebrandt, B, Symeonidis, A, Cermak, J, Fenaux, P, Kelaidi, C, Pfeilstöcker, M, Nösslinger, T, Sekeres, M, Maciejewski, J, Haase, D, Schanz, J, Seymour, J, Kenealy, M, Weide, R, Lübbert, M, Platzbecker, U, Valent, P, Götze, K, Stauder, R, Blum, S, Kreuzer, K-A, Schlenk, R, Ganser, A, Hofmann, W-K, Aul, C, Krieger, O, Kündgen, A, Haas, R, Hasford, J, Giagounidis, A

“…Myelodysplastic syndromes (MDS) with del(5q) are considered to have a benign course of the disease. In order to address the issue of the propensity of those…”
Get full text

Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes by Nösslinger, T., Tüchler, H., Germing, U., Sperr, W. R., Krieger, O., Haase, D., Lübbert, M., Stauder, R., Giagounidis, A., Valent, P., Pfeilstöcker, M.

“…Background: The International Prognostic Scoring System (IPSS) is the golden standard to assess prognosis in myelodysplastic syndromes (MDS). The aim of this…”
Get full text

Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant by d'Amore, Francesco, Leppä, Sirpa, Silva, Maria Gomes da, Relander, Thomas, Lauritzsen, Grete Fossum, Brown, Peter De Nully, Pezzutto, Antonio, Doorduijn, Jeanette K., Weidmann, Eckhart, van Gelder, Michel, Hoof, Achiel Van, Christiansen, Ilse, Fagerli, Unn Merete, Hagberg, Hans, Lugtenburg, P.J., Walewski, Jan, Wu, Ka Lung, Demuynck, Hilde Maria, Fijnheer, Rob, Christensen, Jacob H., Jankovská, Milada, Josefsson, Pär L., Kluin-Nelemans, Hanneke, Mariz, Jose Mario, Merup, Mats A., Noesslinger, Thomas, Van Den Neste, Eric, Zijlstra, Josée M, Hopfinger, Georg, Prochazka, VIT, Jantunen, Esa, Boudova, Ludmila, Cabecadas, Jose, Chott, Andreas, Delabie, Jan M.A., de Leval, Laurence, Diepstra, Arjan, Karjalainen-Lindsberg, Marja-Liisa, Noergaard, Peter, Rosenwald, Andreas, Rymkiewicz, Grzegorz, Sundström, Christer, Truemper, Lorenz, Wulf, Gerald, Chong, Lauren, Bouska, Alyssa, Smith, Lynette, Gisselbrecht, Christian, Ziepert, Marita, Loeffler, Markus, Liestol, Knut, Steidl, Christian, Gascoyne, Randy D., Scott, David W., Altmann, Bettina, Iqbal, Javeed, Chan, Wing C, Toldbod, Helle

“…[§ share last authorship] Background: In 2000-2010, the first large prospective trials in peripheral T-cell lymphoma (PTCL) showed outcomes burdened by high…”
Get full text

Lupus anticoagulant and thrombosis in splenic marginal zone lymphoma by Gebhart, J, Lechner, K, Skrabs, C, Sliwa, T, Müldür, E, Ludwig, H, Nösslinger, T, Vanura, K, Stamatopoulos, K, Simonitsch-Klupp, I, Chott, A, Quehenberger, P, Mitterbauer-Hohendanner, G, Pabinger, I, Jäger, U, Geissler, K

“…Abstract Introduction Splenic marginal zone lymphoma (SMZL) is a rare low-malignant Non-Hodgkin lymphoma (NHL), in which immune mediated paraneoplastic…”
Get full text

Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma by KAUFMANN, H, ACKERMANN, J, ZIELINSKI, C, DRACH, J, BALDIA, C, NÖSSLINGER, T, WIESER, R, SEIDL, S, SAGASTER, V, GISSLINGER, H, JÄGER, U, PFEILSTÖCKER, M

“…Molecular and genetic events associated with the transition from monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM) are still…”
Get full text

Infusion reactions to the chimeric EGFR inhibitor cetuximab—change to the fully human anti-EGFR monoclonal antibody panitumumab is safe by Resch, G., Schaberl-Moser, R., Kier, P., Kopetzky, G., Scheithauer, W., Sliwa, T., Greil, R., Nösslinger, T., Mayrbäurl, B., Thaler, J.

Get full text